Clinical Trials Sponsored by Elios Therapeutics, LLC

Total 413 results

Grifols Therapeutics LLC

Recruiting

A Study to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment (SMT) Compared to Placebo Plus SMT to Prevent Infections in Participants With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia

Bacterial Infections | B-cell Chronic Lymphocytic Leukemia | Hypogammaglobulinemia

United States, Bulgaria, Poland, Romania, Serbia
Minneamrita Therapeutics LLC

Recruiting

Minnelide™ Capsules Alone and in Combination With Paclitaxel in Advanced Gastric Cancer

Gastric Cancer

Korea, Republic of
Cerevel Therapeutics, LLC

Recruiting

Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing

Opioid Use Disorder

United States
Cerevel Therapeutics, LLC

Recruiting

A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Schizophrenia

United States, Bulgaria
Cardix Therapeutics LLC

Not yet recruiting

An Exploratory Safety and Efficacy Clinical Study of CARDIX-101 for the Treatment of Chronic Bradycardia

Bradycardia
Cerevel Therapeutics, LLC

Recruiting

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

Apathy in Dementia

United States, Canada
Cloudbreak Therapeutics, LLC

Completed

Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction

Meibomian Gland Dysfunction

United States
Cerevel Therapeutics, LLC

Completed

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

Healthy Volunteers

United States
Cerebral Therapeutics LLC

Terminated

Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization

Refractory Epilepsy

Israel, Australia
Cerevel Therapeutics, LLC

Active, not recruiting

Fixed-Dose Trial in Early Parkinson's Disease (PD) (TEMPO-1)

Parkinson Disease

Spain, United States, Australia, Bulgaria, Canada, Czechia, France, Germany, Israel, Italy, Poland, Ukraine
Cerevel Therapeutics, LLC

Completed

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

Healthy Participants

United States
RSV Therapeutics LLC

Completed

A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19

Sars-CoV-2 Infection

Russian Federation
Cerevel Therapeutics, LLC

Active, not recruiting

The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants

Healthy

United States
Grifols Therapeutics LLC

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

Primary Immunodeficiency

United States
Cerevel Therapeutics, LLC

Completed

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Hepatic Impairment

United States
Sention Therapeutics, LLC

Active, not recruiting

A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism

Hypothyroidism

United States
Cerevel Therapeutics, LLC

Completed

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

Schizophrenia | Blood Pressure

United States
Grifols Therapeutics LLC

Terminated

A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients (COVID-19)

COVID-19 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Spain
Grifols Therapeutics LLC

Completed

Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)

COVID-19

United States
Cerevel Therapeutics, LLC

Completed

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Schizophrenia

United States
Oui Therapeutics, LLC

Completed

Feasibility Study of a Software Application for Patients Hospitalized After Suicidal Ideation or Suicide Attempts

Suicidal Ideation | Suicide, Attempted

United States
LIB Therapeutics LLC

Completed

Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

Hypercholesterolemia

United States
Cerevel Therapeutics, LLC

Completed

A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia

Schizophrenia

United States
Oryn Therapeutics, LLC

Withdrawn

A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia

COVID-19

United States
Cerevel Therapeutics, LLC

Completed

An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects

Healthy Subjects

United States
Trius Therapeutics LLC

Completed

Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

Bacterial Infection

United States
Grifols Therapeutics LLC

Completed

Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human) (GamaSTAN)

Anti-Hepatitis A Antibody Levels in Heathy Subjects

United States
Kastle Therapeutics, LLC

Completed

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol (FOCUS FH)

Hypercholesterolemia | Heterozygous Familial

United States, Italy, Poland, Ukraine, United Kingdom, Germany, Hong Kong, Taiwan, Spain, Argentina, Belgium, Israel, Malaysia, South Africa, Turkey, Netherlands, Korea, Republic of, Canada, New Zealand, Russian Federation, Brazil, Austral... and more
Trius Therapeutics LLC

Completed

TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Skin and Subcutaneous Tissue Bacterial Infections

United States, Argentina, Australia, Brazil, Germany, Mexico, New Zealand, Poland, Russian Federation, South Africa, Spain
Grifols Therapeutics LLC

Completed

A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency

Alpha₁-Antitrypsin Deficiency

United States
Trius Therapeutics LLC

Completed

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

Renal Impairment

United States
Grifols Therapeutics LLC

Completed

Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP

Purpura, Thrombocytopenic, Idiopathic

United States
Grifols Therapeutics LLC

Completed

Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency (KIDS)

Primary Immunodeficiency

United States
Olatec Therapeutics LLC

Completed

Phase 1 Safety and PK Study of OLT1177 Capsules

Healthy Volunteers

United States
Olatec Therapeutics LLC

Completed

Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee

Osteoarthritis of the Knee

United States
Grifols Therapeutics LLC

Completed

Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults (ChAMP)

Alpha 1-Antitrypsin Deficiency

United States
Grifols Therapeutics LLC

Completed

The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency (STAMP)

Alpha 1-Antitrypsin Deficiency

United States, United Kingdom
Olatec Therapeutics LLC

Completed

Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects

Healthy Volunteers

United States
Rise Therapeutics LLC

Not yet recruiting

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

Melanoma | Basal Cell Carcinoma | Squamous Cell Carcinoma | Melanoma Recurrent | Squamous Cell Cancer | Basal Cell Cancer
Rise Therapeutics LLC

Not yet recruiting

R-2487 in Patients With Sjogren's Syndrome (SS) (R-2487-SS-01)

Sjogren's Syndrome | Sjögren | Sjögren Syndrome, Unspecified
Constant Therapeutics LLC

Recruiting

TXA127 in Non-Ambulant Patients With DMD Cardiomyopathy

DMD-Associated Dilated Cardiomyopathy

Israel
Rise Therapeutics LLC

Recruiting

R-2487 in Patients With Rheumatoid Arthritis (R-2487-RA01)

Arthritis, Rheumatoid

United States
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

Panic Disorder

United States
Olatec Therapeutics LLC

Recruiting

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Arthritis | Joint Pain | Gout | Gout Flare | Gouty Arthritis | Acute Gout Flare | Gout Attack

United States, Spain, France
Minneamrita Therapeutics LLC

Recruiting

Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas

Metastatic Adenocarcinoma of the Pancreas

Korea, Republic of
Cloudbreak Therapeutics, LLC

Recruiting

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

Pterygium

United States, China, India, Australia, New Zealand
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary, Puerto Rico, Ukraine
Cerevel Therapeutics, LLC

Recruiting

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary
Rapa Therapeutics LLC

Recruiting

RAPA-201 Therapy of Solid Tumors

Breast Cancer | Head and Neck Cancer | Gastric Cancer | Solid Tumor | Bladder Cancer | Triple Negative Breast Cancer | Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Malignant Melanoma | Carcinoma of Unknown Primary | Squamous Cell Carcinoma of Larynx | Squamous Cell Carcinoma of Oral Cavity | Squamous Cell Carcinoma of Nasopharynx and other conditions

United States
Grifols Therapeutics LLC

Recruiting

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

Alpha1-Antitrypsin Deficiency

United States

3

Subscribe